Sestrin 2 confers primary resistance to sorafenib by simultaneously activating AKT and AMPK in hepatocellular carcinoma
出版年份 2018 全文链接
标题
Sestrin 2 confers primary resistance to sorafenib by simultaneously activating AKT and AMPK in hepatocellular carcinoma
作者
关键词
-
出版物
Cancer Medicine
Volume 7, Issue 11, Pages 5691-5703
出版商
Wiley
发表日期
2018-10-12
DOI
10.1002/cam4.1826
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- IRAK1 Augments Cancer Stemness and Drug Resistance via the AP-1/AKR1B10 Signaling Cascade in Hepatocellular Carcinoma
- (2018) Bowie Y. Cheng et al. CANCER RESEARCH
- Sestrin2 facilitates glutamine-dependent transcription of PGC-1α and survival of liver cancer cells under glucose limitation
- (2018) Ashish Kumar et al. FEBS Journal
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Hepatocellular carcinoma
- (2018) Alejandro Forner et al. LANCET
- The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma
- (2018) Daniela Pollutri et al. Cell Death & Disease
- Rage induces hepatocellular carcinoma proliferation and sorafenib resistance by modulating autophagy
- (2018) Jun Li et al. Cell Death & Disease
- Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1
- (2018) Rosalba D’Alessandro et al. CELLULAR ONCOLOGY
- A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells
- (2018) Eroje M. Ahmed et al. CELLULAR ONCOLOGY
- Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma
- (2018) Zuzana Macek Jilkova et al. Oncotarget
- Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance
- (2017) Peter Dietrich et al. GUT
- By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma
- (2017) Sainan Li et al. INTERNATIONAL JOURNAL OF CANCER
- FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib
- (2017) Lixia Gao et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Sestrin2 and sestrin3 suppress NK-92 cell-mediated cytotoxic activity on ovarian cancer cells through AMPK and mTORC1 signaling
- (2017) Xuejin Wang et al. Oncotarget
- Efficacy of sorafenib in patients with hepatocellular carcinoma after resection: a meta-analysis
- (2017) Jin Shang et al. Oncotarget
- Capsaicin exerts synergistic antitumor effect with sorafenib in hepatocellular carcinoma cells through AMPK activation
- (2017) Alicia Bort et al. Oncotarget
- Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines
- (2017) Yuki Haga et al. PLoS One
- Hypoxia Enhances Tumor-Stroma Crosstalk that Drives the Progression of Hepatocellular Carcinoma
- (2016) Yuri Cho et al. DIGESTIVE DISEASES AND SCIENCES
- AMP-activated protein kinase: a cellular energy sensor that comes in 12 flavours
- (2016) Fiona A. Ross et al. FEBS Journal
- ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1α
- (2016) Fu-Quan Wu et al. JOURNAL OF HEPATOLOGY
- Serum miR-16: A Potential Biomarker for Predicting Melanoma Prognosis
- (2016) Sen Guo et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib
- (2016) Aline Houessinon et al. Molecular Cancer
- Quantitative proteomics and phosphoproteomics on serial tumor biopsies from a sorafenib-treated HCC patient
- (2016) Eva Dazert et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- AMPK: An Energy-Sensing Pathway with Multiple Inputs and Outputs
- (2016) D. Grahame Hardie et al. TRENDS IN CELL BIOLOGY
- AMPK-mediated up-regulation of mTORC2 and MCL-1 compromises the anti-cancer effects of aspirin
- (2016) Mei Gao et al. Oncotarget
- Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1
- (2015) Ji-chao Wei et al. ACTA PHARMACOLOGICA SINICA
- PSMD10/gankyrin induces autophagy to promote tumor progression through cytoplasmic interaction with ATG7 and nuclear transactivation of ATG7 expression
- (2015) Tao Luo et al. Autophagy
- Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma
- (2015) Jiang Chen et al. CANCER LETTERS
- Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib
- (2015) Naoki Ishijima et al. CANCER SCIENCE
- Caveolin-1 Confers Resistance of Hepatoma Cells to Anoikis by Activating IGF-1 Pathway
- (2015) Wenqing Tang et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells
- (2015) Xiaofang Sun et al. HEPATOLOGY
- Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer
- (2015) Wei-Ching Chen et al. Oncotarget
- The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell killing
- (2015) Valentina Tesori et al. Scientific Reports
- BIRC6 promotes hepatocellular carcinogenesis: Interaction of BIRC6 with p53 facilitating p53 degradation
- (2014) Wenqing Tang et al. INTERNATIONAL JOURNAL OF CANCER
- Sestrin2 Protein Positively Regulates AKT Enzyme Signaling and Survival in Human Squamous Cell Carcinoma and Melanoma Cells
- (2014) Baozhong Zhao et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines
- (2014) SUNBIN LING et al. ONCOLOGY REPORTS
- Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK–mTORC1 signaling
- (2013) Claudia Fumarola et al. BREAST CANCER RESEARCH AND TREATMENT
- Sestrins Orchestrate Cellular Metabolism to Attenuate Aging
- (2013) Jun Hee Lee et al. Cell Metabolism
- The Noncytotoxic Dose of Sorafenib Sensitizes Bel-7402/5-FU Cells to 5-FU by Down-Regulating 5-FU-Induced Nrf2 Expression
- (2013) Suna Zhou et al. DIGESTIVE DISEASES AND SCIENCES
- Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma
- (2013) Yingjian Liang et al. HEPATOLOGY
- The degree of liver injury determines the role of p21 in liver regeneration and hepatocarcinogenesis in mice
- (2013) Laura Elisa Buitrago-Molina et al. HEPATOLOGY
- In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma
- (2012) Alex Y. Chang et al. ANTI-CANCER DRUGS
- Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth
- (2012) Hannah van Malenstein et al. CANCER LETTERS
- Sestrin2 integrates Akt and mTOR signaling to protect cells against energetic stress-induced death
- (2012) I Ben-Sahra et al. CELL DEATH AND DIFFERENTIATION
- Sestrins Activate Nrf2 by Promoting p62-Dependent Autophagic Degradation of Keap1 and Prevent Oxidative Liver Damage
- (2012) Soo Han Bae et al. Cell Metabolism
- Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity
- (2012) Kuen-Feng Chen et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Mechanisms of acquired resistance to targeted cancer therapies
- (2012) Mark R Lackner et al. Future Oncology
- EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib
- (2012) Zakaria Ezzoukhry et al. INTERNATIONAL JOURNAL OF CANCER
- Resistance and Escape From Antiangiogenesis Therapy: Clinical Implications and Future Strategies
- (2012) Justin N. Bottsford-Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells
- (2012) Marie-José Blivet-Van Eggelpoël et al. JOURNAL OF HEPATOLOGY
- Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies
- (2012) Shubha Bagrodia et al. Pigment Cell & Melanoma Research
- Fangchinoline induces autophagic cell death via p53/sestrin2/AMPK signalling in human hepatocellular carcinoma cells
- (2011) Ning Wang et al. BRITISH JOURNAL OF PHARMACOLOGY
- Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma
- (2011) Satoshi Shimizu et al. INTERNATIONAL JOURNAL OF CANCER
- Sorafenib induces preferential apoptotic killing of a drug- and radio-resistant hep G2 cells through a mitochondria-dependent oxidative stress mechanism
- (2010) Jeng-Fong Chiou et al. CANCER BIOLOGY & THERAPY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of the Multitargeted Tyrosine Kinase Inhibitors Imatinib, Dasatinib, Sunitinib, and Sorafenib on Mitochondrial Function in Isolated Rat Heart Mitochondria and H9c2 Cells
- (2008) Yvonne Will et al. TOXICOLOGICAL SCIENCES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now